Discover investment opportunities in Best Crispr Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Crispr Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Crispr Stocks using our Smart AI Filter.
6 stocks found for "Best Crispr Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.60 | ±100.0% | -2.7 | 0.00% | |||
2.12 | ±100.0% | -8.3 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
1.39 | ±92.0% | -3.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What key factors should investors consider when evaluating CRSP stock?
A: Investors should look at CRISPR Therapeutics' leading position in gene editing, partnerships with major biotech firms, financial health, and pipeline progress. Their focus on hemoglobinopathies and immuno-oncology offers growth potential, but clinical trial outcomes and regulatory hurdles can impact valuation.
Q: How does EDIT's market position influence its investment appeal?
A: EDIT holds a strong position in gene editing with proprietary technology. Its collaboration with pharmaceutical players enhances development prospects. However, investors should be cautious of its operational losses and regulatory risks inherent in biotech investments.
Q: What growth opportunities do NTLA stocks present?
A: Intellia Therapeutics is pioneering in-vivo gene editing, providing growth potential. Strategic partnerships and a strong R&D pipeline underpin its capabilities. Investors should consider clinical trial results and collaboration expansion as key growth indicators.
Q: Why might BEAM be of interest to long-term growth investors?
A: Beam Therapeutics focuses on base editing, a next-gen CRISPR technology. Its advanced genomic platforms and collaborations position it for innovation. Long-term investors may view its pipeline and potential market impact favorably, despite current profitability challenges.
Q: Are there income opportunities with VERV stocks?
A: While Verve Therapeutics is an early-stage biotech, focusing primarily on cardiovascular gene editing, it typically doesn't cater to income-seeking investors. Its potential lies in long-term capital appreciation dependent on clinical advancements.
Q: What are the risks of investing in SGMO stocks?
A: Sangamo Therapeutics faces biotech sector risks like clinical outcomes, competition, and regulatory hurdles. Though it has diverse partnerships and platforms, its financial performance and R&D outcomes play critical roles in its stock valuation.